pharmaceutical business development
CASE STUDIES
OUR SERVICES
A Romanian pharmaceutical company wanted business development support. Find out how we helped >>
A university wanted a commercial appraisal and valuation of an antibody technology. Find out more >>
A biotech company’s business development resources were stretched. Find out how we provided interim management support >>
The Government of Egypt wanted a thorough strategic review and benchmarking of their pharmaceutical industry. Find out more >>
WHAT A SATISFIED CLIENT SAYS ABOUT US...
“Many thanks indeed for a superbly compiled commercial appraisal...I've never been less than fully satisfied with your superbly crafted reports.”
Dr Albert Chan
Overseas Markets Director
Special Products Limited
© Estradia Consulting Limited
RECENT PROJECTS
We have worked with many international clients ranging from individual entrepreneurs and small companies through to pharmaceutical companies and governments. We always strive to add value with what we do and only take on projects where we have the experience and skills required. Below are some examples of recent projects.
Case Study 7
A small company which sold unlicensed medicines wanted to develop its
business outside of UK.
We were able to identify the different regulatory environments
for unlicensed medicines in other European countries. We subsequently identified
potential distributors in the target countries and rapidly negotiated and concluded
commercial terms.
Case Study 8
A pharmaceutical company had a novel formulation of
an established neurology product in Phase I of development. Future development costs
were higher than expected, and the company wanted an independent valuation of the
market potential before deciding whether to commit to development.
Our appraisal of
the market identified that the target indication was too small to justify development
of the product, as this would involve a high risk with little opportunity for a return
on the investment. However our analysis also revealed that the product was likely
to be effective in several much larger market sectors. Following our discounted cash
flow and Net Present Value analysis the company decided to focus the development
on the newly identified target indications.
<< Back to previous Case Studies